In a groundbreaking partnership, Apollo Hospitals and Siemens Healthineers have joined hands to drive innovation in liver healthcare through cutting-edge advancements in artificial intelligence (AI) and imaging technologies. This collaboration aims to revolutionize the management of liver diseases by enhancing patient care pathways, from early detection and risk assessment to monitoring intervention and therapy response. With a focus on combating the rising prevalence of liver diseases in India, particularly Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), also known as NAFLD, the partnership combines technical prowess and clinical expertise to develop state-of-the-art healthcare solutions. MASLD, affecting 9% to 32% of the population in India, poses a significant public health challenge, especially among individuals who are overweight, obese, or diabetic. Through the utilization of AI-driven disease progression models, the collaboration seeks to enable early detection of fibrosis, facilitating timely interventions, cost-effective screening, and improved patient outcomes. Dr. Sangita Reddy, Joint Managing Director of Apollo Hospitals, emphasized the transformative potential of AI in redefining non-invasive diagnostics for liver disease, underscoring the importance of increased awareness, early detection, and effective management strategies. The partnership reflects Apollo’s commitment to integrating intelligent systems into clinical practices to enhance diagnostic accuracy, proactive patient management, and precision population health strategies. Similarly, Hariharan Subramanian, managing director of Siemens Healthcare, stressed the importance of advanced diagnostic tools and technologies in prioritizing early diagnosis and prevention of liver diseases, ultimately improving patient outcomes and quality of life. The formalization of the Master Research Agreement (MRA) in March 2025, following the 2024 Memorandum of Understanding, marks a significant milestone in this collaborative effort. The signing ceremony for the MRA Addendum in July 2025 in Hyderabad signifies a pivotal moment in advancing diagnostic and interventional ultrasound imaging research, setting the stage for groundbreaking developments in liver healthcare.
Tags: None
Read more from pharmabiz.com